Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) PT at $195.92

Ascendis Pharma A/S (NASDAQ:ASND) has received an average recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $195.92.

A number of research firms recently issued reports on ASND. Evercore ISI upped their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 17th. JPMorgan Chase & Co. dropped their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research note on Wednesday, October 23rd. Jefferies Financial Group boosted their price objective on Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research report on Tuesday, August 13th. TD Cowen increased their target price on Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, Oppenheimer reissued an “outperform” rating and set a $190.00 price target (up from $180.00) on shares of Ascendis Pharma A/S in a research note on Tuesday, September 17th.

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock opened at $125.28 on Friday. Ascendis Pharma A/S has a 52 week low of $86.54 and a 52 week high of $161.00. The stock has a market capitalization of $7.60 billion, a P/E ratio of -13.46 and a beta of 0.64. The stock has a fifty day moving average of $133.42 and a 200-day moving average of $133.68.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. On average, research analysts forecast that Ascendis Pharma A/S will post -7.24 earnings per share for the current year.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors have recently added to or reduced their stakes in ASND. Assetmark Inc. bought a new position in Ascendis Pharma A/S during the 3rd quarter worth approximately $331,000. Jackson Square Capital LLC bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at $1,441,000. Harbor Capital Advisors Inc. increased its position in shares of Ascendis Pharma A/S by 67.2% during the third quarter. Harbor Capital Advisors Inc. now owns 87,302 shares of the biotechnology company’s stock worth $13,035,000 after buying an additional 35,102 shares during the period. Pursue Wealth Partners LLC bought a new position in Ascendis Pharma A/S during the third quarter worth $217,000. Finally, Rice Hall James & Associates LLC lifted its holdings in Ascendis Pharma A/S by 5.9% in the third quarter. Rice Hall James & Associates LLC now owns 160,614 shares of the biotechnology company’s stock valued at $23,981,000 after buying an additional 8,958 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.